Population pharmacokinetic modelling and design of a bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation

Clinical Pharmacokinetics

Volumn 51, Issue 3, 2012, Pages 175-186

  Monchaud, Caroline ^a,b   De Winter, Brenda C ^a   Knoop, Christiane ^c   Estenne, Marc ^c   Reynaud Gaubert, Martine ^d   Pison, Christophe ^e   Stern, Marc ^f   Kessler, Romain ^g   Guillemain, Romain ^h   Marquet, Pierre ^a,b   Rousseau, Annick ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c ERASME HOSPITAL   (Belgium)

^d AIX MARSEILLE UNIVERSITY   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f FOCH HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Lung transplant; Pharmacokinetic modelling; Pharmacokinetics; Pharmacology; Population pharmacokinetics; Tacrolimus.

Indexed keywords

ALANINE; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A5; GLYCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; GRAFT RECIPIENT; HUMAN; LUNG CYSTIC FIBROSIS; LUNG FIBROSIS; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NONLINEAR SYSTEM; PHARMACOGENETICS; PHARMACOLOGICAL PARAMETERS; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BAYES THEOREM; BELGIUM; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857090385     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11594760-000000000-00000     Document Type: Article

References (35)

1. Christie JD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010 Oct; 29 (10): 1104-18
2. Saint-Marcoux F, Knoop C, Debord J, et al. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet 2005; 44 (12): 1317-28 (Pubitemid 41832572)
3. Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. Clin Pharmacokinet 2009; 48 (7): 419-62
4. Monchaud C,Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II. Clin Pharmacokinet 2009; 48 (8): 489-516
5. Boer F. Drug handling by the lungs. Br J Anaesth 2003 Jul; 91 (1): 50-60 (Pubitemid 36857315)
6. Egan TM, Detterbeck FC, Mill MR, et al. Long term results of lung transplantation for cystic fibrosis. Eur J Cardiothorac Surg 2002 Oct; 22 (4): 602-9 (Pubitemid 35286946)
7. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice.Clin Ther 2002Mar; 24 (3): 330-50 (Pubitemid 34275858)
8. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009 Apr; 31 (2): 139-52
9. Benkali K, Premaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 2009; 48 (12): 805-16
10. Nei M. Analysis of gene diversity in subdivided populations. Proc Natl Acad Sci USA 1973 Dec; 70 (12): 3321-3
11. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2011
12. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM user's guide: part V. Introductory guide. San Francisco (CA):NONMEMProject Group, University of California, 1992
13. Musuamba FT, Mourad M, Haufroid V, et al. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. Ther Drug Monit 2009 Dec; 31 (6): 734-42
14. Molinaro M, Regazzi MB, Pasquino S, et al. Pharmacokinetics of tacrolimus during the early phase after heart transplantation. Transplant Proc 2001 May; 33 (3): 2386-9 (Pubitemid 33762751)
15. Press RR, Ploeger BA, den HJ, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009 Apr; 31 (2): 187-97
16. Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit 2004 Feb; 26 (1): 23-30 (Pubitemid 38140906)
17. Savic RM, Jonker DM, Kerbusch T, et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007 Oct; 34 (5): 711-26 (Pubitemid 47477040)
18. Etienne MC, Chatelut E, Pivot X, et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion: a NONMEM analysis. Eur J Cancer 1998 Jan; 34 (1): 92-7 (Pubitemid 28123387)
19. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokineticpharmacodynamic models: I. Models for covariate effects. J Pharmacokinet Biopharm 1992 Oct; 20 (5): 511-28 (Pubitemid 23034413)
20. Knoop C, Thiry P, Saint-Marcoux F, et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transplant 2005 Jun; 5 (6): 1477-82 (Pubitemid 40839441)
21. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005 Sep; 79 (3): 241-57 (Pubitemid 41196689)
22. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions.AmAssoc Pharm Sci J 2009 Sep; 11 (3): 558-69
23. Jadhav PR, Gobburu JV. A new equivalence based metric for predictive check to qualify mixed-effects models. Am Assoc Pharm Sci J 2005; 7 (3): E523-31
24. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999 Apr; 59 (1): 19-29 (Pubitemid 29125558)
25. D'Argenio DZ, Schumitzki A. ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software. Los Angeles (CA): Biomedical Simulations Resource, 1997
26. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 Aug; 9 (4): 503-12
27. Walker S, Habib S, Rose M, et al. Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis. Transplant Proc 1998 Jun; 30 (4): 1519-20 (Pubitemid 28309670)
28. Sam WJ, Tham LS, Holmes MJ, et al. Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients. Clin Pharmacokinet 2006; 45 (1): 59-75 (Pubitemid 43145015)
29. Sam WJ, Aw M, Quak SH, et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 2000 Dec; 50 (6): 531-41 (Pubitemid 32010014)
30. Staatz CE, Willis C, Taylor PJ, et al. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 2003 Feb; 9 (2): 130-7 (Pubitemid 36204563)
31. Garcia Sanchez MJ, Manzanares C, Santos-Buelga D, et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 2001 Jan; 40 (1): 63-71 (Pubitemid 32182114)
32. Regazzi M, Rinaldi M, Molinaro M, et al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients. Ther Drug Monit 1999; 21 (1): 2-7 (Pubitemid 29077448)
33. Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002 Dec; 72 (6): 660-9 (Pubitemid 36021005)
34. Lee PI. Design and power of a population pharmacokinetic study. Pharm Res 2001 Jan; 18 (1): 75-82 (Pubitemid 32299625)
35. Hoogtanders K, van der Heijden J, Christiaans M, et al. Dried blood spot measurement of tacrolimus is promising for patient monitoring. Transplantation 2007 Jan 27; 83 (2): 237-8 (Pubitemid 46185219)